DropGenie raises $5M to miniaturize CRISPR gene editing

Montréal and Boston-based biotech startup DropGenie has raised $5 million USD in a seed-plus round led by BDC Capital’s Thrive Fund, with participation from Skeleton Key, Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Québec. The funding will accelerate commercialization of its microfluidics platform, which shrinks CRISPR gene-editing experiments to a fraction of their usual scale.

The company’s technology uses electrical signals to manipulate droplets of liquid on a tiny chip, replacing traditional lab equipment with a single device. This method reportedly requires significantly fewer cells and reagents than conventional CRISPR screens, a key advantage when working with scarce or expensive biological samples. DropGenie’s CEO, Alison Hirukawa, has described early-stage drug discovery as labor-intensive, often relying on manual processes that waste limited patient material. By automating these workflows, the startup aims to make high-throughput genetic screening more efficient.

DropGenie’s first product, expected to launch commercially in the second quarter of next year, will offer automated lab workflows as a service. The company has already partnered with pharmaceutical companies like AbbVie and UCB Pharma, as well as life science instrument firms Danaher and Sartorius. These collaborations suggest industry interest in its ability to generate large datasets from minimal input—an increasingly valuable capability as AI plays a larger role in drug development. Some investors see potential in the startup’s approach to producing the kind of data needed for computational models.

The funding will also support hiring and additional partnerships as DropGenie expands its team across its Montréal and Cambridge, Massachusetts offices. While the technology is still early in its commercialization, its focus on automation aligns with broader efforts in biotech to reduce the time and cost of translating genetic research into therapies. Recent coverage of AI-driven drug discovery startups highlighted the importance of computational scale, but DropGenie’s platform addresses a different challenge: the physical constraints of biological material.

The startup’s value proposition is clear: smaller samples, lower costs, faster results. However, its long-term success will depend on whether its miniaturized platform can match the accuracy and reliability of traditional methods. For now, its partnerships and investor backing indicate confidence in its potential to streamline a labor-intensive part of the drug discovery process. If it delivers, DropGenie could help make therapies that rely on scarce patient samples more practical. The next key milestone will be its commercial launch next year—and whether early customers find its approach effective at scale.

Sources: betakit.com